Last $45.39 USD
Change Today +4.09 / 9.90%
Volume 2.4M
JUNO On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

juno therapeutics inc (JUNO) Snapshot

Open
$40.22
Previous Close
$41.30
Day High
$45.50
Day Low
$39.31
52 Week High
01/12/15 - $61.70
52 Week Low
12/19/14 - $34.71
Market Cap
4.1B
Average Volume 10 Days
2.5M
EPS TTM
--
Shares Outstanding
90.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for JUNO THERAPEUTICS INC (JUNO)

juno therapeutics inc (JUNO) Related Businessweek News

No Related Businessweek News Found

juno therapeutics inc (JUNO) Details

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. The company’s additional product candidates comprise CD171, a cell-surface adhesion molecule to treat neuroblastoma; MUC-16, a protein for treating ovarian cancers; IL-12, a cytokine to overcome the inhibitory effects; ROR-1, a protein for the treatment of non-small cell lung, triple negative breast, pancreatic, and prostate cancers; and WT-1, an intracellular protein to treat adult myeloid leukemia and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers. It has license and collaboration agreements with Fred Hutchinson Cancer Research Center and Memorial Sloan Kettering Cancer Center; and license agreement with St. Jude Children’s Research Hospital. The company was formerly known as FC Therapeutics, Inc. and changed its name to Juno Therapeutics, Inc. in October 2013. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington.

70 Employees
Last Reported Date: 12/19/14
Founded in 2013

juno therapeutics inc (JUNO) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $229.5K
Compensation as of Fiscal Year 2013.

juno therapeutics inc (JUNO) Key Developments

Juno Therapeutics Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 08:30 AM

Juno Therapeutics Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 08:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Hans E. Bishop, Co-Founder, Chief Executive Officer, President and Director.

Juno Therapeutics Inc.(NasdaqGS:JUNO) added to NASDAQ Composite Index

Juno Therapeutics Inc. will be added to the NASDAQ Composite Index.

Juno Therapeutics Appoints Maggie Wilderotter to its Board of Directors

Juno Therapeutics announced that Maggie Wilderotter, Chairman and CEO of Frontier Communications Corporation, has been appointed to the company's board of directors. Wilderotter, the eighth member of the company's board of directors, brings significant public company experience as both a board member and a senior executive to the company's board. Before joining Frontier Communications in 2004, Wilderotter was Senior Vice President of Worldwide Public Sector at Microsoft.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JUNO:US $45.39 USD +4.09

JUNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for JUNO.
View Industry Companies
 

Industry Analysis

JUNO

Industry Average

Valuation JUNO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 11.8x
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JUNO THERAPEUTICS INC, please visit www.junotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.